• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Expression levels of genes implicated in the working mechanism of lenalidomide predict treatment response in lower risk myelodysplastic syndrome patients.

作者信息

In't Hout Florentien E M, Scheele Thessa N, Westers Theresia M, Alhan Canan, Duetz Carolien, Cremers Eline M P, Visser-Wisselaar Heleen A, Verbrugge Annelies, Chitu Dana A, Van der Reijden Bert A, De Graaf Aniek O, Van de Loosdrecht Arjan A, Jansen Joop H

机构信息

Department of Laboratory medicine, Laboratory of Hematology, Radboud University Medical Centre, Nijmegen, The Netherlands; Department of Hematology, Radboud University Medical Centre, Nijmegen.

Department of Laboratory medicine, Laboratory of Hematology, Radboud University Medical Centre, Nijmegen.

出版信息

Haematologica. 2025 Mar 1;110(3):772-776. doi: 10.3324/haematol.2024.286157.

DOI:10.3324/haematol.2024.286157
PMID:39385740
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11873685/
Abstract
摘要

相似文献

1
Expression levels of genes implicated in the working mechanism of lenalidomide predict treatment response in lower risk myelodysplastic syndrome patients.与来那度胺作用机制相关的基因表达水平可预测低危骨髓增生异常综合征患者的治疗反应。
Haematologica. 2025 Mar 1;110(3):772-776. doi: 10.3324/haematol.2024.286157.
2
High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide.伴有孤立性5q缺失的低危骨髓增生异常综合征中全长cereblon mRNA的高水平与来那度胺的疗效有关。
Eur J Haematol. 2015 Jul;95(1):27-34. doi: 10.1111/ejh.12457. Epub 2014 Oct 31.
3
Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.增加来那度胺剂量治疗伴有 5 号染色体异常的高危骨髓增生异常综合征和急性髓系白血病的临床疗效。
Haematologica. 2011 Jul;96(7):963-71. doi: 10.3324/haematol.2010.039669.
4
The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes.来那度胺在治疗5号染色体缺失及其他骨髓增生异常综合征患者中的作用。
Curr Opin Hematol. 2007 Mar;14(2):123-9. doi: 10.1097/MOH.0b013e328016847a.
5
Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34(+) cells from patients with del(5q) myelodysplastic syndrome.来那度胺诱导 CD34(+) 细胞中 miR-145 表达与 del(5q) 骨髓增生异常综合征患者临床反应和反应持续时间的相关性。
Haematologica. 2013 Mar;98(3):409-13. doi: 10.3324/haematol.2012.066068. Epub 2012 Aug 28.
6
An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome.红系分化特征可预测骨髓增生异常综合征对来那度胺的反应。
PLoS Med. 2008 Feb;5(2):e35. doi: 10.1371/journal.pmed.0050035.
7
Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion.来那度胺治疗对伴有 5q 染色体缺失的骨髓增生异常综合征患者造血的影响。
Haematologica. 2010 Mar;95(3):406-14. doi: 10.3324/haematol.2009.010876. Epub 2009 Sep 22.
8
Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q).来那度胺治疗前后骨髓增生异常综合征伴孤立性5号染色体缺失（5q-）患者的全基因组DNA甲基化分析
Ann Hematol. 2021 Jun;100(6):1463-1471. doi: 10.1007/s00277-021-04492-1. Epub 2021 Apr 27.
9
A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes.一项 miRNA 筛选研究发现，miR-192-5p 与骨髓增生异常综合征患者对阿扎胞苷和来那度胺治疗的反应相关。
Clin Epigenetics. 2023 Feb 20;15(1):27. doi: 10.1186/s13148-023-01441-9.
10
Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes.促炎蛋白 S100A9 和肿瘤坏死因子-α 抑制骨髓增生异常综合征中促红细胞生成素的生成。
Haematologica. 2017 Dec;102(12):2015-2020. doi: 10.3324/haematol.2016.158857. Epub 2017 Oct 5.

本文引用的文献

1
Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial.低剂量来那度胺与安慰剂在非输血依赖的低危、del(5q)骨髓增生异常综合征患者中的比较（SintraREV）：一项随机、双盲、3 期试验。
Lancet Haematol. 2024 Sep;11(9):e659-e670. doi: 10.1016/S2352-3026(24)00142-X. Epub 2024 Jul 18.
2
Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.骨髓增生异常综合征的分子国际预后评分系统
NEJM Evid. 2022 Jul;1(7):EVIDoa2200008. doi: 10.1056/EVIDoa2200008. Epub 2022 Jun 12.
3
Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial.
骨髓增生异常综合征患者使用或不使用红细胞生成刺激剂时来那度胺反应的决定因素：HOVON89 试验。
Leukemia. 2024 Apr;38(4):840-850. doi: 10.1038/s41375-024-02161-6. Epub 2024 Jan 31.
4
Next-generation therapy for lower-risk MDS.用于低危 MDS 的下一代治疗方法。
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):59-64. doi: 10.1182/hematology.2023000520.
5
New Approaches to Myelodysplastic Syndrome Treatment.骨髓增生异常综合征治疗的新方法。
Curr Treat Options Oncol. 2022 May;23(5):668-687. doi: 10.1007/s11864-022-00965-1. Epub 2022 Mar 23.
6
How we manage adults with myelodysplastic syndrome.成人骨髓增生异常综合征的治疗策略。
Br J Haematol. 2020 Jun;189(6):1016-1027. doi: 10.1111/bjh.16206. Epub 2019 Sep 30.
7
A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes.一条钙和钙蛋白酶依赖性途径决定了骨髓增生异常综合征对来那度胺的反应。
Nat Med. 2016 Jul;22(7):727-34. doi: 10.1038/nm.4127. Epub 2016 Jun 13.
8
Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS).来那度胺治疗的伴有孤立性5号染色体长臂缺失（5q-）的骨髓增生异常综合征患者中TP53突变的患病率、克隆动力学及临床影响：德国骨髓增生异常综合征研究组（GMDS）一项前瞻性多中心研究的结果
Leukemia. 2016 Sep;30(9):1956-9. doi: 10.1038/leu.2016.111. Epub 2016 May 2.
9
Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.来那度胺联合或不联合促红细胞生成素治疗不伴有 5q 缺失的输血依赖型低危 MDS 对红细胞生成刺激剂抵抗
Leukemia. 2016 Apr;30(4):897-905. doi: 10.1038/leu.2015.296. Epub 2015 Oct 26.
10
Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS.来那度胺诱导del(5q)骨髓增生异常综合征中CK1α的泛素化和降解。
Nature. 2015 Jul 9;523(7559):183-188. doi: 10.1038/nature14610. Epub 2015 Jul 1.